Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, Gentaur another in time delivery
Publication Date : //
Colorectal cancer (CRC) is frequently complicated by metastatic disease, with the liver being the most common site of metastasis. Surgical resection is the only realistic cure for colorectal liver metastases; however only 10-25% of cases are initially resectable. The introduction of combination chemotherapy has improved survival rates by enabling 10-20% cases with previously unresectable hepatic metastases to become amenable to surgery. Recent results with the biologic agent bevacizumab, a chimeric human-mouse monoclonal antibody against VEGF, and cetuximab, a chimeric human-mouse monoclonal antibody against EGF receptor, have shown that they improve clinical surgical outcomes when added to current first-line regimens in patients with metastatic colorectal cancer. Dual biologic therapy in combination with chemotherapy has, however, yielded disappointing results. Identification of biological markers is expected to help determine which patients are most likely to respond to these newer agents and thus improve targeted therapy.
Authors : Barugel Mario E , Vargas Carlos , Krygier Waltier Gabriel ,
Related products :
52062 Aachen Deutschland
Support Karolina Elandt
Tel: +49 0241 40 08 90 86, +49 0241 95 78 94 78, +49 0241 40 08 90 86
Fax: (+49) 241 56 00 47 88
Logistic :0241 40 08 90 86
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
[email protected] | Gentaur | Gentaur
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123
Canada Montreal +15149077481
Ceská republika Praha +420246019719
Finland Helsset +358942419041
Magyarország Budapest +3619980547
US New York+17185132983
WP1589: Folate-Alcohol and Cancer Pathway
WP1968: genetic alternations of lung cancer
WP1971: Integrated Cancer pathway
WP1984: Integrated Breast Cancer Pathway
WP2107: pathways in human cancer
WP2249: Metastatic brain tumor
WP2256: Integrated Pancreatic Cancer Pathway
WP2263: Prostate Cancer
WP2291: Deregulation of Rab and Rab Effector Genes in Bladder Cancer
WP2335: sGC Cancer
WP2361: Gastric cancer network 1
WP2363: Gastric cancer network 2
WP2367: Private Pancreatic Cancer
WP2377: Integrated Pancreatic Cancer Pathway
WP2411: Cancer prevention Q
WP2429: Cancer prevention Q
Related Genes :
 A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial.
 Validation of clinical risk score for colorectal liver metastases resected in a contemporary multicenter cohort.
 The Multidisciplinary Management of Colorectal Cancer: Present and Future Paradigms.
 A Time-Trend Economic Analysis of Cancer Drug Trials.
 Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions.
 Healing of osteonecrosis of the jaw (ONJ) after discontinuation of denosumab in a patient with bone metastases of colorectal cancer: a case report and hypothesis.
 Effect of liver regeneration on malignant hepatic tumors.
 Role of cetuximab in first-line treatment of metastatic colorectal cancer.
 Tissue-based biomarkers predicting outcomes in metastatic colorectal cancer: a review.
 EURECCA consensus conference highlights about colon & rectal cancer multidisciplinary management: the radiology experts review.
Enter catalog number :